If you made any changes in Pure these will be visible here soon.

Personal profile


Jenny Lee is a medical oncologist who is part of the Precision Cancer Therapy Laboratory as the clinical lead. Her research interests include melanoma and lung cancer, especially in understanding the mechanisms behind immunotherapy response and resistance, and biomarker discovery.

Fingerprint Dive into the research topics where Jenny Lee is active. These topic labels come from the works of this person. Together they form a unique fingerprint.

  • 7 Similar Profiles
Melanoma Medicine & Life Sciences
DNA Medicine & Life Sciences
Neoplasms Medicine & Life Sciences
Biomarkers Medicine & Life Sciences
Immunotherapy Medicine & Life Sciences
Therapeutics Medicine & Life Sciences
Antibodies Medicine & Life Sciences
Mutation Medicine & Life Sciences

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Projects 2016 2017

Research Outputs 2014 2019

  • 482 Citations
  • 7 h-Index
  • 12 Article
  • 4 Meeting abstract
  • 2 Review article
  • 1 Chapter

Circulating cytokines predict immune-related toxicity in melanoma patients receiving anti-PD-1 based immunotherapy

Lim, S. Y., Lee, J. H., Nur Gide, T., Menzies, A. M., Guminski, A., Carlino, M. S., Breen, E., Yang, J. Y. H., Ghazanfar, S., Kefford, R. F., Scolyer, R. A., Long, G. V. & Rizos, H., Mar 2019, In : Clinical Cancer Research. 25, 5, p. 1557-1563 7 p.

Research output: Contribution to journalArticleResearchpeer-review

Confidence Intervals

Emerging novel therapies in overcoming resistance to targeted therapy

Pinho, A. V., Lee, J. H. & Rizos, H., 2019, Current applications for overcoming resistance to targeted therapies. Szewczuk, M. R., Qorri, B. & Sambi, M. (eds.). Switzerland: Springer, Springer Nature, p. 223-258 36 p. (Resistance to Targeted Anti-Cancer Therapeutics; vol. 20).

Research output: Chapter in Book/Report/Conference proceedingChapterResearchpeer-review

Physiologic Monitoring
Leukemia, Myelogenous, Chronic, BCR-ABL Positive

Monitoring melanoma using circulating free DNA

Diefenbach, R. J., Lee, J. H. & Rizos, H., 13 Feb 2019, In : American Journal of Clinical Dermatology. 20, 1, p. 1-12 12 p.

Research output: Contribution to journalArticleResearchpeer-review

Nucleic Acids
Polymerase Chain Reaction

Neoadjuvant dabrafenib combined with trametinib for resectable, stage IIIB–C, BRAFV600 mutation-positive melanoma (NeoCombi): a single-arm, open-label, single-centre, phase 2 trial

Long, G. V., Saw, R. P. M., Lo, S., Nieweg, O. E., Shannon, K. F., Gonzalez, M., Guminski, A., Lee, J. H., Lee, H., Ferguson, P. M., Rawson, R. V., Wilmott, J. S., Thompson, J. F., Kefford, R. F., Ch'ng, S., Stretch, J. R., Emmett, L., Kapoor, R., Rizos, H., Spillane, A. J. & 2 othersScolyer, R. A. & Menzies, A. M., 1 Jul 2019, In : The Lancet Oncology. 20, 7, p. 961-971 11 p.

Research output: Contribution to journalArticleResearchpeer-review

Neoadjuvant Therapy

Pharmacokinetic and cytokine profiles of melanoma patients with dabrafenib and trametinib-induced pyrexia

Kim, H. Y., Duong, J. K., Gonzalez, M., Long, G. V., Menzies, A. M., Rizos, H., Lim, S. Y., Lee, J. & Boddy, A. V., 8 Apr 2019, In : Cancer Chemotherapy and Pharmacology. 83, 4, p. 693-704 12 p.

Research output: Contribution to journalArticleResearchpeer-review



Sydney Vital travel scholarship

Jenny Lee (Recipient), 26 Jul 2018